Investors & Media

Webcast ImageWebcast
Isis Pharmaceuticals’ Webcast re: Akcea Therapeutics (Live)
06/04/15 at 1:00 p.m. ET
Isis Pharmaceuticals’ Webcast re: Akcea Therapeutics
Thursday, June 4, 2015 1:00 p.m. ET  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar
Webcast ImageWebcast
Goldman Sachs 36th Annual Global Healthcare Conference (Live)
06/10/15 at 2:40 p.m. PT
Goldman Sachs 36th Annual Global Healthcare Conference
Wednesday, June 10, 2015 2:40 p.m. PT  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar
Webcast ImageWebcast
Isis Pharmaceuticals’ Annual Stockholder Meeting (Live)
06/30/15 at 2:00 p.m. ET
Isis Pharmaceuticals’ Annual Stockholder Meeting
Tuesday, June 30, 2015 2:00 p.m. ET  through Tuesday, June 30, 2015 
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar
Company Profile
We are the leading company in RNA-targeted drug discovery and development, exploiting a proven novel drug discovery platform we created to generate a broad pipeline of first-in-class or best-in-class antisense drugs. The efficiency and broad applicability of our drug discovery platform allows us to discover and develop antisense drugs to treat a wide range of diseases with an emphasis on cardiovascular, metabolic, severe and rare diseases, including neurological disorders, and cancer. The efficiency of our drug discovery technology allows us to employ a unique business strategy designed to maximize the value of our drugs and technology while maintaining an effective cost structure that limits our cash needs. Our business strategy is supported by our platform technology, our robust pipeline of drugs and our multifaceted partnering strategy, which have enabled us to focus on doing what we do best - to discover and develop novel antisense drugs.
Recent Press ReleasesMore >>
DateTitle 
05/28/15Webcast Alert: Akcea Therapeutics Conference Call
CARLSBAD, Calif., May 28, 2015 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announces the following webcast: What: Akcea Therapeutics Webcast When: Thursday, June 4 at 1:00 p.m. ET / 10:00 a.m. PT Where: www.isispharm.com How: Live on the Internet.  Simply log onto our website listed above. If you are unable to participate duri... 
Printer Friendly Version
05/05/15Isis Reports Financial Results and Highlights for First Quarter 2015
- Pro Forma Operating Income Driven by $46 Million in Partner Payments - Conference Call Webcast Tuesday, May 5, 11:30 a.m. ET at www.isispharm.com CARLSBAD, Calif., May 5, 2015 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) today reported pro forma operating income of $4.0 million for the three months ended March 31, 2015 compared to a pro forma net operating loss of $22.6 million for the same period in 2014.  Isis' significantly improved financial results were due to higher re... 
Printer Friendly Version
05/04/15Isis Pharmaceuticals Licenses ISIS-FXI Rx to Bayer to Develop and Commercialize for the Prevention of Thrombosis
--Bayer to develop ISIS-FXI Rx broadly for the prevention of thrombosis-- --Transaction maximizes value of the ISIS-FXI Rx program-- --Partnership provides Isis with significant potential to participate in commercial success of ISIS-FXI Rx-- CARLSBAD, Calif., May 4, 2015 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) has entered into an exclusive license agreement with Bayer HealthCare (Bayer) to develop and commercialize ISIS-FXIRx for the prevention of thrombo... 
Printer Friendly Version
04/30/15Isis Pharmaceuticals Earns $10 Million Milestone Payment From Biogen
CARLSBAD, Calif., April 30, 2015 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today it has earned a $10 million milestone payment from Biogen associated with the validation of an undisclosed target to treat a neurological disorder.  This is the ninth program to advance, which includes four drugs in development, under Isis' and Biogen's broad strategic alliance to discover and develop novel therapies to treat neurological and neuromuscular disorders.  "Together with B... 
Printer Friendly Version
Upcoming EventsMore >>
DateTitle
06/04/15 1:00 p.m. ET
Isis Pharmaceuticals’ Webcast re: Akcea Therapeutics
06/10/15 2:40 p.m. PT
Goldman Sachs 36th Annual Global Healthcare Conference
LocationRancho Palos Verdes, CA
06/30/15 2:00 p.m.
through
06/30/15 5:00 p.m. ET
Isis Pharmaceuticals’ Annual Stockholder Meeting
LocationCarlsbad, CA

For more information requests, please visit our Information Request page.

If you are interested in Isis Pharmaceuticals’ investment details,
please visit our Investor FAQ page.

Powered by Thomson Reuters
Data Provided by Thomson Reuters